{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=16", "query": { "intervention": "Phase 1b", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 2480, "total_pages": 248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T03:07:47.640Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02657343", "title": "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-03-09", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02657343" }, { "nct_id": "NCT00002243", "title": "A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Calanolide A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarawak MediChem Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 9, "location_summary": "Miami, Florida • Vero Beach, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002243" }, { "nct_id": "NCT01138085", "title": "Safety, Pharmacokinetics (PK) of AKT and MEK Combination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212", "type": "DRUG" }, { "name": "GSK2141795", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2010-05-04", "completion_date": "2014-11-19", "has_results": false, "last_update_posted_date": "2017-11-13", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 10, "location_summary": "Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01138085" }, { "nct_id": "NCT05153408", "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Neoplasms", "Neoplasms by Site", "Lung Diseases", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Adenocarcinoma", "Carcinoma", "Neoplasms by Histologic Type", "Neoplasms, Nerve Tissue", "EGFR C797S", "EGFR C797A", "EGFR L858R", "EGFR Exon 19 Deletion", "EGFR Gene Mutation", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance", "EGFR Activating Mutation", "Thoracic Neoplasms", "Antineoplastic Agents", "Protein Kinase Inhibitors", "EGFR C797G", "EGFR C797X", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "BLU-701", "type": "DRUG" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-01-13", "completion_date": "2022-12-09", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153408" }, { "nct_id": "NCT07610135", "title": "Psilocybin Efficacy With or Without Pimavanserin Pretreatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mood (Psychological Function)", "Well Being", "Mood", "Healthy" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Pimavanserin", "type": "DRUG" }, { "name": "Inactive Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2026-10-30", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07610135" }, { "nct_id": "NCT06627413", "title": "Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia or Schizoaffective" ], "interventions": [ { "name": "Lumateperone Capsule", "type": "DRUG" }, { "name": "Lumateperone LAI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intra-Cellular Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2024-08-23", "completion_date": "2025-11-20", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 4, "location_summary": "Los Alamitos, California • Atlanta, Georgia • Marlton, New Jersey", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06627413" }, { "nct_id": "NCT04190550", "title": "Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin Hydrochloride", "type": "DRUG" }, { "name": "Navtemadlin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-02-04", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 6, "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04190550" }, { "nct_id": "NCT02778204", "title": "Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Days", "sex": "ALL", "summary": "Up to 3 Days" }, "enrollment_count": 47, "start_date": "2017-06-05", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2022-01-04", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02778204" }, { "nct_id": "NCT07216833", "title": "Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Neoplasms", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2026-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07216833" }, { "nct_id": "NCT04340258", "title": "Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HNSCC" ], "interventions": [ { "name": "Cesium-131", "type": "DEVICE" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": 50, "start_date": "2021-02-04", "completion_date": "2026-09-04", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-20T03:07:47.640Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340258" } ] }